Dr. Judith Tsui’s research focuses on the intersection of opioid use disorders, pain, and related co-morbidities (hepatitis C and HIV). Dr. Tsui is an internist who is also board certified in Addiction Medicine through the American Board of Addiction Medicine since 2013. Since 2019 she has served as the Associate Director of the UW Addiction Medicine Fellowship. As a clinician investigator, she seeks to elucidate complex relationships between substance use disorders and co-morbidities and to develop and test novel interventions to improve the lives of patients with addictions. Dr. Tsui also publishes in peer-reviewed journals and contributes to the popular press. View her full CV.

Research Activities and Funding

Development and Evaluation of Effectiveness of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine

NIH/NIDA
R44DA044053
Role: Principal Investigator
06/01/2017–06/30/2020

Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs

NIH/NIDA
1R34DA047660
Role: Principal Investigator
08/01/2019–06/30/2022

Pilot Study of Opioid-Receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol

NIH/NIAAA
UH2AA026193
Role: Principal Investigator
09/20/2017–08/31/2022

Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural Cohort) Data Coordinating Center

NIH
1U24DA048538
Role: Principal Investigator
04/01/2019–03/31/2024

Patient-Centered Models of HCV Care for People who Inject Drugs

PCORI
HPC-1503-28122 
Role: Co-investigator
02/01/2016–01/31/2022
This study aims to explore the best model of care for treating hepatitis C (HCV) in people who inject drugs. This research will compare methods of HCV treatment (directly-observed therapy to patient navigator). Outcomes to be evaluated will include treatment effectiveness (cure) and reinfection rates. This is a national study involving eight US cities (New York, Baltimore, Providence, Boston, Cincinnati, Seattle, San Francisco, and Albuquerque) and up to 1,000 subjects recruited from methadone clinics and community health centers.

Improving Physician Opioid Prescribing for Chronic Pain in HIV-Infected Persons

NIH/NIDA
1R01DA037768
Role: Co-investigator
09/01/2014–08/31/2020

Mentoring the next generation of addiction clinician scientists while responding to the opioid epidemic

NIH/NIDA
R25-DA037756
Role: Mentor
04/01/2019–03/31/2024

University of Washington Provider’s Clinical Support System – Universities

SAMHSA
1H79TI081651
Role: Principal Investigator
09/30/2018–09/29/2021
The UW-PCSS-U project will provide DATA waiver training to medical students and residents with the goal of encouraging fledgling physicians to utilize buprenorphine in the treatment of opioid use disorder (OUD). To accomplish this goal, the project builds on the institution’s existing curriculum that addresses pain and addiction, including pre-clinical and clinical experiences. The program will include an evaluation of provider outcomes (achieving waivers and prescribing).


Previous Funding

SAMHSA Medication-Assisted Treatment (MAT)

The MAT Prescription Drug and Opioid Addiction project provides clinical services centered around buprenorphine treatment through the Adult Medicine Clinic at Harborview Medical Center for patients suffering from opioid use disorders. The program is based on a collaborative care model driven by a nurse care manager that optimizes physician effort.

Advancing Clinical Research Training within Addiction Residency Programs

The RAMS Program enhances research capacity among trainees in the new medical specialty of Addiction Medicine. This program seeks to improve patient care by expanding knowledge about effective prevention and treatment in order to reduce the medical, social, and financial burden of drug abuse and addiction.


View selected publications and contributions to the popular press.